In analogy to highly accurate molecular imaging techniques in other tumor entities (e.g., prostate cancer) [6,11], [68Ga]RM2 positron emission tomography (PET)/computed tomography (CT) targeting the gastrin-releasing peptide receptor (GRPR) could help detecting the oligometastatic stage in patients with BC and might, thus, improve accurate stratification of this patient group. This evidence concerns the gene GRPR and prostate cancer.